Background: Risk factor modification is important in patients with vascular disease. Guidelines suggest that this patient population benefits from a medical regimen of antiplatelets, statins, β-blockers, and angiotensin-converting enzyme (ACE) inhibitors. Materials and Methods: The medical regimen of consecutive patients who presented for major vascular surgery intervention over 18 months was examined. Results: Of the 325 patients identified, 176 (54%) were on antiplatelet treatment, 197 (61%) were on a statin, 180 (55%) on β-blockers, and 146 (54%) on ACE inhibitors. A high-risk subset of 94 smokers with known coronary artery disease, hypertension, and hyperlipidemia or diabetes was identified. In this subset, patients were more likely to be on pharmacologic risk factor modification. Conclusions: Despite recommendations, the pharmacologic risk factor modification of patients prior to vascular surgery remains suboptimal. Increased awareness of the problem and active participation of the vascular specialist are essential to improve compliance with established guidelines.
Criqui MH, Fronek A., Barrett-Connor E., Klauber MR, Gabriel S., Goodman D.The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510-515.
2.
Hiatt WR, Hoag S., Hamman RFEffect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91: 1472-1479.
3.
Criqui MH, Langer RD, Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
4.
Hiatt WR, Wolfel EE, Meier RH, Regensteiner JGSuperiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. 1994;90:1866-1874.
5.
A prospective epidemiological survey of the natural history of chronic critical leg ischaemia. The I.C.A.I. Group (gruppo di studio dell'ischemia cronica critica degli arti inferiori). Eur J Vasc Endovasc Surg. 1996;11: 112-120.
6.
Dormandy JA, Rutherford RBManagement of peripheral arterial disease (PAD). TASC Working Group.TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(pt 2):S1-S296.
7.
Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology . Circulation. 2001;104:1577-1579.
8.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71-86.
9.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360: 7-22.
10.
van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008;102:192-196.
11.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
12.
Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents.A systematic review and meta-analysis. JAMA. 1997;277:739-745.
13.
Ostergren J. , Sleight P., Dagenais G., et al, HOPE study investigators.Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J.2004;25:17-24.
14.
Lindenauer PK, Pekow P., Wang K., et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med . 2005;353:349-361.
15.
Auerbach AD , Goldman L.Beta-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA. 2002;287:1435-1444.
16.
Fleisher LA , Eagle KAClinical practice. Lowering cardiac risk in noncardiac surgery. N Engl J Med.2001; 345:1677-1682.
17.
Beattie WS, Wijeysundera DN, Karkouti K., McCluskey S., Tait G.Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials. Anesth Analg.2008;106: 1039-1048, table of contents.
18.
Bangalore S. , Messerli FH, Kostis JB, Pepine CJCardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50: 563-572.
19.
Rice TW, Lumsden ABOptimal medical management of peripheral arterial disease. Vasc Endovascular Surg. 2006;40:312-327.
20.
Khan S., Flather M., Mister R., et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry . Eur J Vasc Endovasc Surg. 2007;33: 442-450.
21.
Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FAEvidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ. 2004;171: 1189-1192.
22.
Bianchi C., Montalvo V., Ou HW, Bishop V., Abou-Zamzam AM Jr.Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg . 2007;21: 163-166.
23.
Al-Omran M. , Lindsay TF, Major J., Jawas A., Leiter LA, Verma S.Systematic Assessment of Vascular Risk Investigators. Perceptions of Canadian vascular surgeons toward pharmacological risk reduction in patients with peripheral arterial disease. Ann Vasc Surg.2006;20:555-563.
